Диссертация (Роль биологических маркеров в ранней диагностике поражения сердца при хронической болезни почек на додиализной стадии), страница 21
Описание файла
Файл "Диссертация" внутри архива находится в папке "Роль биологических маркеров в ранней диагностике поражения сердца при хронической болезни почек на додиализной стадии". PDF-файл из архива "Роль биологических маркеров в ранней диагностике поражения сердца при хронической болезни почек на додиализной стадии", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата медицинских наук.
Просмотр PDF-файла онлайн
Текст 21 страницы из PDF
–2005. – Vol. 16 (2). – P. 507-513.95. Kronenberg F. Emerging risk factors and markers of chronic kidney diseaseprogression. // Nature Reviews Nephrology. – 2009. – Vol. 5 (12). – P. 677-689.13496. Krown K.A., Page M.T., Nguyen C. et al. Tumor necrosis factor alpha-inducedapoptos in cardiac myocytes: involvement of thensphingolipid signaling cascade incardiac cell death.
// J Clin Invest. – 1996. – Vol. 98. – P. 2854-2865.97. Krum H., Schlaich M., Whitbourn R. et al. Catheter-based renal sympatheticdenervation for resistant hypertension: a multicentre safety and proof-ofprinciplecohort study. // Lancet. – 2009.
– Vol. 373 (9671). – P. 1275–1281.98. Kumbar L., Fein P.A., Rafiq M.A. et al. Pulmonary hypertension in peritonealdialysis patients. // Adv Perit Dial. – 2007. – Vol. 23. – P. 127–131.99. Kuo C.-F., Yu K.-H., Luo S.-F. et al. Role of uric acid in the link between arterialstiffness and cardiac hypertrophy: a cross-sectional study. // Rheumatology(Oxford).– 2010. – Vol. 49 (6).
– P. 1189–1196.100. Levey A.S., Coresh J., Balk E. et al. National Kidney Foundation practiceguidelines for chronic kidney disease: evaluation, classification, and stratification. //Ann Intern Med. – 2003. – Vol. 139 (2). – P. 137-147.101. Levin A., Singer J., Thompson C.R. et al. Prevalent left ventricular hypertrophyin the predialysis population: identifying opportunities for intervention. // Am JKidney Dis. – 1996. – Vol.
27 (3). – P. 347-354.102. Levin A., Thompson C.R., Either J. et al. Left ventricular mass increase in earlyrenal disease: impact of decline in hemoglobin. // Am J Kidney Dis. – 1998. – Vol.34 (1). – P. 125-134.103.Levy D., Garrison R.G., Savage D.D. et al. Prognostic implications ofechocardiographically determined left ventricular mass index in the FraminghamHeart Study.
// N Engl J Med. – 1990. – Vol. 22. – P. 1561-1566.104. Libby P., Okamoto Y., Rocha V.Z. et al. Inflammation in atherosclerosis:transition from theory to practice. // Circ J. – 2010. – Vol.74 (2). – P. 213-220.105. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating thebiology of atherosclerosis.
// Nature. – 2011. – Vol. 473(7347). – P. 317-325.106. London G. Pathophysiology of cardiovascular damage in the early renalpopulation. // Nephrol Dial Transplant. – 2001. – Vol. 16 (Suppl. 2). – P. 3-6.135107. London G.M. Heterogeneity of left ventricular hypertrophy - does it have clinicalimplications? // Nephrol Dial Transplant. – 1998. – Vol. 13. – P. 17-19.108. London G.M., Fabiani F. Left ventriсular dysfunction in end-stage renal disease:echocardiographic insights. // Cardiac dysfunction in chronic uremia. Eds. P.S.Parfrey, J.D. Harnett. Basel: Kluwer Acad Publ.
– 1992. – P. 117-137.109. Lubien Е., DeMaria А., Krishnaswamy Р. et al. Utility of B-natriuretic peptide indetecting diastolic dysfunction: comparison with Doppler velocity recordings. //Circulation. – 2002. – Vol. 105 (5). – Р. 595–601.110. Maisel A.S., McCord J., Nowak R. M. et al. Bedside B-Type natriuretic peptidein the emergency diagnosis of heart failure with reduced or preserved ejectionfraction. Results from the Breathing Not Properly Multinational Study // J Am CollCardiol.
– 2003. – Vol. 41. – Р. 2010–2017.111. Malik F.S., Lavie C.J., Mehra M.R. Renin-angiotensin system: Geneses tobedside. // Am Heart J. – 1997. – Vol. 134. – P. 514-526.112. Marabotti C., Ebert A.G., Palombo C. et al. Causal, ambulatory and stress bloodpressure: relationship with left ventricular mass and filling. // Int J Cardiol.
– 1991. –Vol. 31. – P. 89-96.113. Marco Guazzi, Nazzareno Galie. Pulmonary hypertension in left heart disease. //Eur Respir Rev. – 2012. – Vol. 21 (126). – P. 338–346.114. Mariusz K. Szymanski, Rudolf A. de Boer, Gerjan J. Navis et al. Animal modelsof cardiorenal syndrome: a review. // Heart Fail Rev. – 2012. – Vol. 17 (3). – P. 411–420.115. Mark P. B., Stewart G.A., Gansevoort R.T. et al. Diagnostic potential ofcirculating natriuretic peptides in chronic kidney disease. // Nephrol DialTransplant.– 2006. – Vol. 21.
– P. 402–410.116. Masiha S., Sundstro J., Lind L. Inflammatory markers are associated with leftventricular hypertrophy and diastolic dysfunction in a population-based sample ofelderly men and women. // Journal of Human Hypertension. – 2013. – Vol. 27 (1). –P. 13-27.136117. Masugata H., Senda S., Inukai M. et al. Association between high-sensitivity Creactive protein and left ventricular diastolic function assessed by echocardiographyin patients with cardiovascular risk factors. // Tohoku J Exp Med. – 2011. – Vol.223 (4).
– P. 263-268.118. Mazzali M., Hughes J., Kim Y.G. et al. Elevated uric acid increases bloodpressure in the rat by a novel crystal-independent mechanism. // Hypertension. –2001. – Vol. 38 (5). – P. 1101 –1106.119. McMahon L.P., Roger S.D., Levin A. Development, prevention, and potentialreversal of left ventricular hypertrophy in chronic kidney disease. // J Am SocNephrol. – 2004. – Vol.
15. – P. 1640-1647.120. Melanson S.E.F., Lewandrowski E.L. Laboratory testing for B-type natriureticpeptides (BNP and NT-proBNP). // Am J Clin Pathol. – 2005. – Vol. 124 (Suppl. 1).– P. 122–128.121. Middleton J.P., Pun P.H. Hypertension, chronic kidney disease, and thedevelopment of cardiovascular risk: a joint primacy. // Kidney Int. – 2010.
– Vol.77. – P. 753-755.122.Mitsuhashi H., Yatsuya H., Matsushita K. et al. Uric acid and left ventricularhypertrophy in Japanese men. // Circ J. – 2009. – Vol. 73 (4). – P. 667–672.123. Mottram P.M., Leano R., Marwick T.H. Usefulness of B-type natriuretic peptidein hypertensive patients with exertional dyspnea and normal left ventricular ejectionfraction and correlation with new echocardiographic indexes of systolic and diastolicfunction // Am J Cardiol. – 2003. – Vol. 92.
– Р.1434–1438.124. Muntner P., Anderson A., Charleston J. et al. Hypertension awareness, treatment,and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort(CRIC) Study. // Am J Kidney Dis. – 2010. – Vol. 55 (3). – P. 441-451.125. Muntner P., He J., Hamm L. et al. Renal insufficiency and subsequent deathresulting from cardiovascular disease in the United states. // J Am Soc Nephrol. –2002. – Vol. 13 (3).
– P. 745-753.126. Nakagawa O., Ogawa Y., Itoh H. et al. Rapid transcriotional activation and earlymRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for137brain natriuretic peptide as an “emergency” cardiac hormone against ventricularoverload. // J Clin Invest. – 1995. – Vol. 96. – Р. 1280–1287.127. Navaneethan S.D., Beddhu S. Associations of serum uric acid with cardiovascularevents and mortality in moderate chronic kidney disease. // Nephrol DialTransplant.– 2009. – Vol.
24 (4). – P. 1260–1266.128. O'Hanlon R., O'Shea Р., Ledwidge М. et al. The biological variability of B-typenatriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heartfailure patients // J Card Fail. – 2007. – Vol. 13. – Р. 50-55.129. Oreste F.T., Quagliana A., Sucato V. et al. Hyperuricemia in patients with leftventricular dysfunction. // Acta Medica Mediterranea. – 2013. – Vol.
29. – P. 493496.130. Pabst S., Hammerstingl C., Hundt F. et al. Pulmonary hypertension in patientswith chronic kidney disease on dialysis and without dialysis: results of the PEPPERstudy. // PLoS One. – 2012. – Vol. 7 (4). – P. 305-310.131. Paoletti E., Bellino D., Cassottana P. et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. // Am J Kidney Dis. – 2005. – Vol.
46 (2). – P. 320-327.132. Patel P.C., Ayers C.R., Murphy S.A. et al. Association of Cystatin C with leftventricular structure and function. The Dallas Heart Study. // Circ Heart Fail. –2009. – Vol. 2 (2). – P. 98-104.133. Parfrey P.S., Foley R.N., Harnett J.T. et al. Outcome and risk factors for leftventricular disorders in chronic uremia. // Nephrol Dial Transpl. – 1996. – Vol. 11(7). – P. 1277- 1285.134. Pasotti М., Ghio S., Latini R. et al.
Echocardiographic correlates of plasma BNPin patients with chronic heart failure. // Eur J Echocardiogr. – 2006. – Vol. 7. – Р. 35.135. Passauer J., Pistrosch F., Bussemaker E. et al. Reduced agonist-inducedendothelium-dependent vasodilation in uremia is attributable to an impairment ofvascular nitric oxide. // J Am Soc Nephrol. – 2005.
– Vol. 16. – P. 959–965.136. Pilz S., Iodice S., Zittermann A. et al. Vitamin D status and mortality risk inCKD: a meta-analysis of prospective studies. // Am J Kidney Dis. – 2011. – Vol. 58(3). – P. 374–382.138137. Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of Losartan compared withCaptopril on mortality in patients with symptomatic heart failure: randomized trialthe Losartan Heart Failure Survival Study ELITE II. // Lancet.
